Interleukin-6 inhibition: a therapeutic strategy for the management of adult-onset Still’s disease

Yuko Kaneko, Tsutomu Takeuchi

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)


Introduction: Patients with adult-onset Still’s disease have markedly elevated serum levels of proinflammatory cytokines, such as IL-1β, IL-6, and IL-18, suggesting the potential of these molecules as therapeutic targets. IL-6 accelerates macrophage and cytotoxic T-cell differentiation and neutrophil and macrophage chemotaxis and is one of the most important cytokines in the pathogenesis of adult-onset Still’s disease. Areas covered: The review summarizes the importance of IL-6 in the pathogenesis of adult-onset Still’s disease and clinical aspects of IL-6 inhibition from retrospective and prospective studies. Expert opinion: Adult-onset Still’s disease is a systemic inflammatory disease of unknown etiology and characterized by elevated various proinflammatory cytokines. In particular, serum concentrations of IL-6 is significantly high in patients with active adult-onset Still’s disease, and many case reports, cohort studies and one randomized, placebo-controlled trail have shown the efficacy of IL-6 blockade in patients with adult-onset Still’s disease who were refractory to glucocorticoids and other immunosuppressive treatments. IL-6 inhibition is effective for both systemic and joint manifestations with arthritis improving slowly. There is still a concern over the triggering of macrophage activation syndrome; however, the IL-6 inhibition strategy has introduced better management of adult-onset Still’s disease.

Original languageEnglish
Pages (from-to)79-85
Number of pages7
JournalExpert Opinion on Biological Therapy
Issue number1
Publication statusPublished - 2022


  • Interleukin-6
  • adult-onset Still’s disease
  • tocilizumab

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry


Dive into the research topics of 'Interleukin-6 inhibition: a therapeutic strategy for the management of adult-onset Still’s disease'. Together they form a unique fingerprint.

Cite this